DSIP common uses, half-life, side effects and more

DSIP is a small peptide of nine amino acids. It was first isolated in the 1970s from the blood of sleeping rabbits. It is named for its ability to bring on deep slow-wave sleep. Small human studies in the early 1980s tested it for chronic insomnia and for easing alcohol and opioid withdrawal. Those studies reported some benefit. That early interest never became an approved medicine. Today people use it as an injected sleep and recovery aid taken before bed in the hope of deeper or more restful sleep. It is not approved as a medicine in the United States or Europe and is sold as an unregulated research chemical.

• Deeper and more restful sleep
• Staying asleep through the night
• Calming and stress reduction before bed
• Chronic insomnia (studied in older clinical trials)
• Alcohol and opioid withdrawal (studied in older clinical trials)

Usually nightly before bed in community use

Community use is subcutaneous injection before bed. Most first-hand reports fall around 100 to 200 mcg. The wider reported range runs from about 100 to 500 mcg. Some experienced users go higher. It is taken nightly or in short courses. Some people cycle it with a week or two off to limit tolerance. The 1980s human trials used a very different regimen. They gave a single intravenous dose of about 1.3 to 1.9 mg for a typical adult. That is a different route and roughly ten times the per-injection amount people use now.

No reliable human plasma half-life has been measured. Laboratory tests show free DSIP breaking down within minutes. That short stability does not explain the longer-lasting sleep effects reported in the early trials.

• No side effects were reported in any of the three early trials
• Headache described by users rather than documented in a trial
• Vivid or unusually heavy dreams described by users
• Next-day grogginess described by users
• Injection-site irritation described by users even though every published trial dosed into a vein

No DSIP receptor, gene, or precursor protein has been identified after roughly fifty years of study. There is no settled account of how DSIP works. The original idea linked it to the opioid system because some pain-blocking effects in animals were reversed by an opioid blocker. Other animal effects were not reversed. The opioid role is therefore inconsistent. Other reported actions include shifting the balance of sleep stages, increasing GABA activity, and modulating the stress hormone axis. Most of these come from animal or test-tube work. One direct human study found no change in the stress hormones cortisol or ACTH. These proposed actions remain unconfirmed in humans.

DSIP has genuine human trials. The evidence is old and thin. The insomnia study enrolled six people and the withdrawal study enrolled 67. They were run decades ago with intravenous dosing in a lab and gave mixed results. The best-controlled sleep trial concluded the effect was weak and possibly no better than placebo. The same trial found no real change in sleep structure. Later research is mostly animal or test-tube work. No large modern trial has ever been run. Community reports match this uncertainty. Many users say it does little or nothing while a minority report deeper sleep. The overall evidence is weak and does not establish that it works.

• DSIP is not approved as a medicine in the United States or Europe and is sold as an unregulated research chemical
• The human evidence is old and limited to a few tiny trials that leave its sleep benefits unproven
• No interaction studies exist for combining it with alcohol, sedatives, or other sleep aids
• It has no safety data in pregnancy or breastfeeding and should be avoided in both
• Gray-market material carries real risks of wrong identity, wrong potency, contamination, and poor sterility
• Injected peptides can provoke an immune response that the FDA has specifically flagged for DSIP